• KOL
    • Chronic Migraine
    • Richard B Lipton
    • Richard B Lipton: Influence Statistics

      Richard B Lipton

      Richard B Lipton

      Show email address

      Department of Neurology, Epidemiology and Population Health, and the Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine, Bronx, New York, ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Richard B Lipton:Expert Impact

      Concepts for whichRichard B Liptonhas direct influence:Chronic migraine,Episodic migraine,United states,Acute treatment,Incident dementia,Migraine prevalence,Pain intensity,Cognitive decline.

      Richard B Lipton:KOL impact

      Concepts related to the work of other authors for whichfor which Richard B Lipton has influence:Chronic migraine,Cognitive impairment,Alzheimer disease,Physical activity,Headache disorders,Acute treatment,Gait speed.

      KOL Resume for Richard B Lipton

      Year
      2022

      Department of Neurology, Epidemiology and Population Health, and the Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine, Bronx, New York, USA

      Montefiore, Bronx, NY

      2021

      Department of Neurology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY

      (New York).

      Albert Einstein College of Medicine.

      Bronx)

      2020

      Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Yeshiva University, New York City, NY, United States

      Montefiore Medical Center, 1165 Morris Park Avenue, Rousso Building, Room 332, 10461, Bronx, NY, USA

      Albert Einstein College of Medicine, New York, NY

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Richard B Lipton is among the top experts in the world.
      Concept World rank
      pain interference levels #1
      combination versus ibuprofen #1
      interaction verbal memory #1
      urban elderly cohort #1
      features headache #1
      eneura therapeutics #1
      caffeine 2 #1
      dementia mbt #1
      older ages migraine #1
      migraine progression migraine #1
      unique diagnosis #1
      hv visual memory #1
      migraine clinical #1
      triptan episodic migraine #1
      onset severe headaches #1
      migraine progression frequency #1
      social life migraine #1
      triptans opioids #1
      midas grade #1
      indirect cost consequences #1
      trends dementia incidence #1
      posttraumatic headache headaches #1
      persons severe headache #1
      pfn persons #1
      pgic pimbs #1
      nbrmrresultsamong #1
      ndphr patients #1
      migraine background #1
      ndph medication overuse #1
      migraine triptan #1
      somi4 #1
      seizure odds ratio #1
      multiattribute decision model #1
      wmas ills #1
      apoe4 memory decline #1
      ± pathology #1
      strong evidence evidence #1
      hurt clinical utility #1
      ibms‐ii #1
      pain iim iiv #1
      relaxahead application app #1
      midas scores #1
      apoe4 ester transfer #1
      function cardiovascular risk #1
      allodynia odds ratio #1
      aura cases #1
      chapter social burden #1
      allodynia − #1
      outcomes cameo study #1
      migraine uk #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Richard B Lipton

      KOL-Index: 23496

      BACKGROUND: The strikingly higher prevalence of migraine in females compared with males is one of the hallmarks of migraine. A large global body of evidence exists on the sex differences in the prevalence of migraine with female to male ratios ranging from 2:1 to 3:1 and peaking in midlife. Some data are available on sex differences in associated symptoms, headache-related disability and impairment, and healthcare resource utilization in migraine. Few data are available on corresponding ...

      Known for Severe Headache | Migraine Prevalence | Females Males | Sex Difference | Healthcare Resource Utilization
      KOL-Index: 21193

      OBJECTIVE: This study assessed the efficacy of sumatriptan 50- and 100-mg tablets in the treatment of migraine attacks while the pain is mild rather than moderate/severe.

      BACKGROUND: Results from The Spectrum Study suggested that early treatment of migraine attacks with sumatriptan 50-mg tablets while the pain is mild might enhance pain-free response and reduce headache recurrence.

      METHODS: Retrospective analyses of headaches treated during mild pain were performed using data from 3 ...

      Known for Migraine Pain | Early Intervention | Sumatriptan 50 | 2 Hours | Free Response
      KOL-Index: 20975

      OBJECTIVE: To evaluate and compare healthcare resource use and related costs in chronic migraine and episodic migraine in the USA and Canada.

      BACKGROUND: Migraine is a common neurological disorder that produces substantial disability for sufferers around the world. Several studies have quantified overall costs associated with migraine in general, with recent estimates ranging from $581 to $7089 per year. Although prior studies have characterized the clinical and humanistic burden of ...

      Known for Episodic Migraine | International Burden | Usa Canada | Costs Chronic | Healthcare Resource
      KOL-Index: 19556

      OBJECTIVE: To assess the effectiveness of the nonprescription combination of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain.

      DESIGN: Three double-blind, randomized, parallel-group, single-dose, placebo-controlled studies.

      SETTING: Private practice, referral centers, and general community.

      PATIENTS: Migraineurs with moderate or severe headache pain who met International Headache Society diagnostic criteria for migraine with aura or without aura. The most ...

      Known for Migraine Headache | Aspirin Caffeine | Patients Pain | Nonprescription Combination | Nausea Photophobia
      KOL-Index: 19196

      OBJECTIVE: To assess the efficacy, safety, and tolerability of onabotulinumtoxinA (BOTOX) as headache prophylaxis in adults with chronic migraine.

      BACKGROUND: Chronic migraine is a prevalent, disabling, and undertreated neurological disorder. Few preventive treatments have been investigated and none is specifically indicated for chronic migraine.

      METHODS: The 2 multicenter, pivotal trials in the PREEMPT: Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy clinical program each ...

      Known for Chronic Migraine | Headache Frequency | Onabotulinumtoxina Placebo | Baseline Week | Preempt Clinical
      KOL-Index: 17456

      OBJECTIVE: The objective of this study was to evaluate the efficacy, safety, and tolerability of DFN-02 - a nasal spray comprising sumatriptan 10 mg and a permeation-enhancing excipient (0.2% 1-O-n-Dodecyl-β-D-Maltopyranoside [DDM]) - for the acute treatment of migraine with or without aura in adults.

      BACKGROUND: Prior work has shown that DFN-02, which contains only half the recommended adult dose of sumatriptan found in the original formulation (10 mg vs 20 mg), is more rapidly absorbed ...

      Known for Acute Treatment | Nasal Spray | Dfn02 Placebo | Permeation Enhancer | Sumatriptan 10
      KOL-Index: 16972

      BACKGROUND: Benefits of calcitonin-gene related peptide (CGRP) inhibition have not been established in chronic migraine. Here we assess the safety, tolerability, and efficacy of two doses of TEV-48125, a monoclonal anti-CGRP antibody, in the preventive treatment of chronic migraine.

      METHODS: In this multicentre, randomised, double-blind, double-dummy, placebo-controlled, parallel-group phase 2b study, we enrolled men and women (aged 18-65 years) from 62 sites in the USA who had chronic ...

      Known for Preventive Treatment | Chronic Migraine | Patients Placebo | Safety Tolerability | 675 225
      KOL-Index: 16966

      BACKGROUND: Calcitonin gene-related peptide (CGRP) is crucial in the pathophysiology of migraine. We assessed the safety, tolerability, and efficacy of ALD403, a genetically engineered humanised anti-CGRP antibody, for migraine prevention.

      METHODS: In this randomised, double-blind, placebo-controlled, exploratory, proof-of-concept phase 2 trial, patients aged 18-55 years with five to 14 migraine days per 28-day period were randomly assigned (1:1) via an interactive web response system to ...

      Known for Migraine Patients | 2 Trial | Calcitonin Gene | Placebo Patient | Adverse Event
      KOL-Index: 16907

      BACKGROUND: US Headache Consortium Guidelines state that persons with migraine with headache-related disability should receive certain acute treatments including migraine-specific and other medications. However, many eligible individuals do not receive these therapies. Individuals with migraine may experience barriers to receiving minimal appropriate care. We aimed to identify barriers to care in a population sample of individuals with episodic migraine. We assessed barriers at 3 levels: ...

      Known for Individuals Migraine | Headache Features | Acute Treatments | Midas Score | Diagnosis 3
      KOL-Index: 16868

      BACKGROUND: Calcitonin gene-related peptide (CGRP) is a validated target for the treatment of episodic migraine. Here we assess the safety, tolerability, and efficacy of TEV-48125, a monoclonal anti-CGRP antibody, in the preventive treatment of high-frequency episodic migraine.

      METHODS: In this multicentre, randomised, double-blind, placebo-controlled, phase 2b study, we enrolled men and women (aged 18-65 years) from 62 sites in the USA who had migraine headaches 8-14 days per month. ...

      Known for Preventive Treatment | Episodic Migraine | Safety Tolerability | Phase 2b Study | Patients Placebo
      KOL-Index: 16693

      OBJECTIVE: To evaluate the efficacy and safety of topiramate (100 mg/day) compared with placebo for the treatment of chronic migraine.

      METHODS: This was a randomized, placebo-controlled, parallel-group, multicenter study consisting of 16 weeks of double-blind treatment. Subjects aged 18 to 65 years with 15 or more headache days per month, at least half of which were migraine/migrainous headaches, were randomized 1:1 to either topiramate 100 mg/day or placebo. An initial dose of ...

      Known for Chronic Migraine | Placebo Treatment | Safety Topiramate | 100 Day | Baseline Monthly
      KOL-Index: 16581

      OBJECTIVE: To determine the extent to which variation in the Migraine Disability Assessment (MIDAS) score is associated with headache frequency, pain intensity, headache symptoms, gender, and employment status.

      BACKGROUND: The MIDAS questionnaire is a 7-item questionnaire (with 5 scored items) designed to measure headache-related disability, to improve physician-patient communication, and to identify patients with high treatment needs.

      METHODS: Data from 3 population-based studies (total ...

      Known for Headache Frequency | Pain Intensity | Migraine Disability | Midas Score | United Kingdom
      KOL-Index: 16393

      OBJECTIVE: To compare the effects of oral rizatriptan, sumatriptan, naratriptan, and zolmitriptan on the relief and emergence of nausea during a migraine attack.

      METHODS: Data from five randomized, placebo-controlled, double-blind clinical trials in which oral rizatriptan 10 mg was directly compared with oral sumatriptan 100 mg (N = 772), 50 mg (N = 1168), 25 mg (N = 1180), naratriptan 2.5 mg (N = 406), or zolmitriptan 2.5 mg (N = 571) for the acute treatment of a migraine attack were ...

      Known for 2 Hours | Patients Nausea | Oral Rizatriptan | Migraine Attack | Sumatriptan 50
      KOL-Index: 16229

      OBJECTIVE: To evaluate the association between migraine and cardiovascular disease, including stroke, myocardial infarction, and death due to cardiovascular disease.

      DESIGN: Systematic review and meta-analysis.

      DATA SOURCES: Electronic databases (PubMed, Embase, Cochrane Library) and reference lists of included studies and reviews published until January 2009. Selection criteria Case-control and cohort studies investigating the association between any migraine or specific migraine ...

      Known for Cardiovascular Disease | Association Migraine | Myocardial Infarction | Women Risk | Ischaemic Stroke

      Key People For Chronic Migraine

      Top KOLs in the world
      #1
      Richard B Lipton
      chronic migraine united states acute treatment
      #2
      Stephen David Silberstein
      chronic migraine cluster headache acute treatment
      #3
      David William Dodick
      chronic migraine cluster headache acute treatment
      #4
      Peter James Goadsby
      cluster headache chronic migraine acute treatment
      #5
      Hanschristoph C Diener
      atrial fibrillation cluster headache chronic migraine
      #6
      Marcelo Eduardo Bigal
      chronic migraine preventive treatment temporomandibular disorders

      Department of Neurology, Epidemiology and Population Health, and the Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine, Bronx, New York, USA | Department of Neurology, Albert Einstein College of Medicine, Bronx, Ne

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.